All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) Completed $110 million private placement equity financing, extending cash runway through 2026 SAN CARLOS, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc . (NASDAQ: CRGX) , a clinical-stage biotechnology company positioned to advance next generation, potentially... Read More